[go: up one dir, main page]

PL2121989T3 - Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR - Google Patents

Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR

Info

Publication number
PL2121989T3
PL2121989T3 PL08742061T PL08742061T PL2121989T3 PL 2121989 T3 PL2121989 T3 PL 2121989T3 PL 08742061 T PL08742061 T PL 08742061T PL 08742061 T PL08742061 T PL 08742061T PL 2121989 T3 PL2121989 T3 PL 2121989T3
Authority
PL
Poland
Prior art keywords
egfr antibody
antibody therapy
ras mutations
ras
mutations
Prior art date
Application number
PL08742061T
Other languages
English (en)
Other versions
PL2121989T5 (pl
Inventor
Daniel Freeman
Todd Juan
Robert Radinsky
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2121989(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PL2121989T3 publication Critical patent/PL2121989T3/pl
Publication of PL2121989T5 publication Critical patent/PL2121989T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL08742061.8T 2007-03-13 2008-03-11 Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR PL2121989T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13
PCT/US2008/003312 WO2008112269A2 (en) 2007-03-13 2008-03-11 K-ras mutations and anti-egfr antibody therapy
EP08742061.8A EP2121989B2 (en) 2007-03-13 2008-03-11 K-ras mutations and anti-egfr antibody therapy

Publications (2)

Publication Number Publication Date
PL2121989T3 true PL2121989T3 (pl) 2014-07-31
PL2121989T5 PL2121989T5 (pl) 2023-03-06

Family

ID=39689242

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08742061.8T PL2121989T5 (pl) 2007-03-13 2008-03-11 Mutacje K-RAS oraz terapia przeciwciałem anty-EGFR
PL12154109T PL2465950T3 (pl) 2007-03-13 2008-03-11 Mutacje k-ras oraz terapia przeciwciałem anty-egfr

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12154109T PL2465950T3 (pl) 2007-03-13 2008-03-11 Mutacje k-ras oraz terapia przeciwciałem anty-egfr

Country Status (21)

Country Link
US (3) US20080293055A1 (pl)
EP (2) EP2465950B1 (pl)
JP (1) JP2010521153A (pl)
AR (1) AR065687A1 (pl)
AU (1) AU2008226803A1 (pl)
CA (1) CA2680326A1 (pl)
CL (1) CL2008000717A1 (pl)
CY (2) CY1115333T1 (pl)
DK (2) DK2465950T3 (pl)
ES (2) ES2635051T3 (pl)
HR (2) HRP20140360T4 (pl)
HU (1) HUE033695T2 (pl)
LT (1) LT2465950T (pl)
MX (1) MX2009009787A (pl)
PE (1) PE20081880A1 (pl)
PL (2) PL2121989T5 (pl)
PT (2) PT2465950T (pl)
RS (2) RS53265B2 (pl)
SI (2) SI2121989T2 (pl)
TW (1) TW200902553A (pl)
WO (1) WO2008112269A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3181705A1 (en) 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
JP2013523178A (ja) * 2010-04-12 2013-06-17 レスポンス ジェネティクス，インコーポレイティド Ｋｒａｓプライマーおよびプローブ
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
JP6397765B2 (ja) * 2011-11-11 2018-09-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102393608B1 (ko) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP2977464A4 (en) * 2013-03-19 2016-10-19 Toppan Printing Co Ltd PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
JP2019507585A (ja) 2015-12-17 2019-03-22 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａの分析による腫瘍遺伝子コピー数を決定するための方法
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin-Elmer Corp., Foster City, Calif. Proben zusammensetzung und verfahren
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1161563A2 (en) 1999-03-15 2001-12-12 PE Corporation (NY) Probe/mobility modifier complexes for multiplex nucleic acid detection
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
PL375064A1 (pl) 2002-05-20 2005-11-14 Abgenix, Inc. Leczenie raka nerki przy użyciu przeciwciał skierowanych przeciwko EGFr
CA2527321A1 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP2439285B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2592155B2 (en) * 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
WO2006047481A2 (en) * 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
CN102007220A (zh) 2005-04-01 2011-04-06 安姆根有限公司 表皮生长因子受体基因拷贝数
CN101155932A (zh) * 2005-04-14 2008-04-02 默克专利有限公司 基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
WO2007001868A1 (en) * 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
ATE520979T1 (de) 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US8293501B2 (en) * 2006-09-12 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy

Also Published As

Publication number Publication date
US10030270B2 (en) 2018-07-24
ES2458626T3 (es) 2014-05-06
RS53265B2 (sr) 2022-06-30
EP2121989A2 (en) 2009-11-25
US11155876B2 (en) 2021-10-26
RS56422B1 (sr) 2018-01-31
ES2458626T5 (es) 2022-04-29
MX2009009787A (es) 2009-09-22
HUE033695T2 (en) 2017-12-28
US20190048423A1 (en) 2019-02-14
PT2121989E (pt) 2014-04-30
US20120264129A1 (en) 2012-10-18
CA2680326A1 (en) 2008-09-18
AR065687A1 (es) 2009-06-24
DK2121989T4 (da) 2022-06-20
CY1119112T1 (el) 2018-02-14
US20080293055A1 (en) 2008-11-27
PE20081880A1 (es) 2008-12-31
PT2465950T (pt) 2017-10-17
EP2121989B1 (en) 2014-01-22
LT2465950T (lt) 2017-10-10
SI2121989T1 (sl) 2014-06-30
DK2465950T3 (en) 2017-10-09
WO2008112269A3 (en) 2008-11-20
TW200902553A (en) 2009-01-16
ES2635051T3 (es) 2017-10-02
HRP20140360T1 (hr) 2014-05-23
HRP20171509T1 (hr) 2017-11-17
JP2010521153A (ja) 2010-06-24
HRP20140360T4 (hr) 2022-06-10
EP2121989B2 (en) 2022-03-09
AU2008226803A1 (en) 2008-09-18
EP2465950A3 (en) 2013-03-13
SI2465950T1 (sl) 2017-11-30
CY1115333T1 (el) 2017-01-04
DK2121989T3 (da) 2014-04-28
SI2121989T2 (sl) 2022-05-31
CL2008000717A1 (es) 2008-09-22
EP2465950A2 (en) 2012-06-20
PL2465950T3 (pl) 2017-12-29
RS53265B (sr) 2014-08-29
WO2008112269A2 (en) 2008-09-18
PL2121989T5 (pl) 2023-03-06
EP2465950B1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
LT2465950T (lt) K-ras mutacijos ir anti-egfr antikūnų terapija
PL2412828T3 (pl) Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
GB0719644D0 (en) Therapeutic compounds and their use
EP2038041A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
GB0803018D0 (en) Therapeutic compounds and their use
ZA200806723B (en) Combination therapy using anti-EGFR and anti-Her2 antibodies
GB0804685D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB2460178B (en) Depsipeptides and their therapeutic use
GB2460181B (en) Depsipeptides and their therapeutic use
EP2142648A4 (en) SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX
IL206420A0 (en) Azetidine derivatives, their preparation and their application in therapy
GB0812913D0 (en) Therapeutic compounds and their use
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB2460180B (en) Depsipeptides and their therapeutic use
GB0802128D0 (en) Therapeutic compounds and their use
HK1139182A (en) K-ras and b-raf mutations and anti-egfr antibody therapy
GB0705517D0 (en) Therapeutic compounds and their use
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
EP2234667A4 (en) DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT
GB0614538D0 (en) Therapeutic Compounds And Their Use